What's in the Cards for Amgen (AMGN) This Earnings Season?
https://www.zacks.com/stock/news/2264395/what-s-in-the-cards-for-amgen-amgn-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-2264395
Apr 29, 2024 - Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
0
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
https://www.zacks.com/stock/news/2265330/will-these-5-drug-biotech-stocks-beat-q1-earnings-forecast?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2265330
Apr 30, 2024 - Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
0
Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings
https://www.zacks.com/stock/news/2267471/here-s-what-key-metrics-tell-us-about-amgen-amgn-q1-earnings?cid=CS-ZC-FT-fundamental_analysis|nfm-2267471
May 02, 2024 - The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0
Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC
https://www.zacks.com/stock/news/2197836/amgen-s-amgn-tarlatamab-bla-gets-fda-priority-tag-for-sclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2197836
Dec 14, 2023 - Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.
0
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras
https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718
Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
0
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
https://www.zacks.com/stock/news/2209160/amgen-amgn-suffers-a-larger-drop-than-the-general-market-key-insights?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2209160
Jan 11, 2024 - Amgen (AMGN) reachead $303.10 at the closing of the latest trading day, reflecting a -0.48% change compared to its last close.
0
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
https://www.zacks.com/stock/news/2210202/are-you-a-momentum-investor-this-1-stock-could-be-the-perfect-pick?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2210202
Jan 15, 2024 - Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
0
Top Research Reports for Novartis, Amgen & Palo Alto Networks
https://www.zacks.com/commentary/2214881/top-research-reports-for-novartis-amgen-palo-alto-networks?cid=CS-ZC-FT-research_daily-2214881
Jan 24, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Novartis AG (NVS), Amgen Inc. (AMGN) and Palo Alto Networks, Inc. (PANW).
0
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218010
Jan 30, 2024 - Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Drug, Biotech Stocks' Q4 Earnings Due on Feb 6: AMGN, LLY & More
https://www.zacks.com/stock/news/2221113/drug-biotech-stocks-q4-earnings-due-on-feb-6-amgn-lly-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2221113
Feb 05, 2024 - Let's take a look at four biotech, drug companies, AMGN, LLY, GILD and EXEL, slated to release quarterly results on Feb 6.
0